Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.59 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.49 |
| ▸ | SQLE | Q14534 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6907669 | 1.00 | KDM1A (0.59) | KDM1APTPN1SQLEKMT2AMAPT | |
| SCHEMBL11571569 | 0.89 | PTPN1 (0.48) | KDM1APTPN1 | |
| SCHEMBL11571568 | 0.89 | PTPN1 (0.48) | KDM1APTPN1 | |
| SCHEMBL2579524 | 0.85 | KDM1A (0.71) | KDM1APTPN1SQLEKMT2AMAPT | |
| SCHEMBL29663830 | 0.83 | KDM1A (0.64) | KDM1APTPN1SQLEKMT2AALDH1A1 | |
| SCHEMBL8735440 | 0.83 | KDM1A (0.64) | KDM1APTPN1SQLEKMT2AALDH1A1 | |
| SCHEMBL6902845 | 0.82 | PTPN1 (0.61) | KDM1APTPN1KMT2AMEN1CYP3A4 | |
| SCHEMBL6902850 | 0.82 | PTPN1 (0.61) | KDM1APTPN1KMT2AMEN1CYP3A4 | |
| SCHEMBL11388757 | 0.82 | KDM1A (0.67) | KDM1APTPN1SQLEKMT2AMAPT | |
| SCHEMBL11388752 | 0.82 | KDM1A (0.67) | KDM1APTPN1SQLEKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6703527-B2 | REACTING ALLYL ALCOHOL COMPOUND SUCH AS 2E,6E-3,7,11-TRIMETHYL-2,6,10-DODECATRIEN-1-OL WITH HYDRIDE ACCEPTOR SUCH AS 2-NITROBENZALDEHYDE IN THE PRESENCE OF AN ALUMINIUM ALKOXIDE AS AN OPPENAUER OXIDATION CATALYST | NIKKEN CHEMICALS CO., LTD. (JP) | 2004-03-09 | — | — | US | disclosed |
| US-20020198411-A1 | Method for oxidation of allyl alcohol | NIKKEN CHEMICALS CO., LTD. (JP) | 2002-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198411-A1 | Method for oxidation of allyl alcohol | ADH1A, ADH1C, ADH5 | KDM1A 1170/4885PTPN1 4791/4885SQLE 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.